Introduction
Hepatocellular carcinoma (HCC) is the sixth most common malignancy worldwide with approximately 626,000 new cancer cases per year [1] . Unfortunately, its incidence approximates its mortality, 598,000 per year, resulting in HCC being the third most common cause of cancer death. In the United States, the incidence of HCC is increasing due to the rise in hepatitis C virus infection and the subsequent risk of cirrhosis in these individuals [2, 3] . Advances in treatment of HCC have recently been made with sorafenib, an oral multikinase inhibitor which targets the Raf kinase and vascular endothelial growth factor (VEGF) pathways [4] [5] [6] . Improvements in overall survival by about 31% have been reported in separate phase III trials conducted in Western countries and in Asia. The survival improvements in predominately Child-Pugh A patients in these trials led to the approval of sorafenib and its acceptance as a new standard therapy in advanced HCC patients.
Similar to the development of sorafenib, an increased understanding of the molecular alterations characteristic of HCC has led to the identification of potential therapeutic targets. One candidate is the 26S proteasome, an ATPdependent multicatalytic protease of the ubiquitinproteasome pathway that governs the ordered and temporal degradation of key regulatory proteins [7] [8] [9] . These mediators (for example, p53, p21, p27, NF-kB) are critical to sustaining HCC cells and regulate transcription and the cell cycle; they are integral to apoptosis, angiogenesis and metastasis. For example, the tumor suppressor gene, p53, has a mutation frequency in HCC ranging from 15% to 42% in HCC [10] and hepatitis B and C viral proteins are known to interfere with p53 function [11, 12] . The HBVx protein hinders p53 entry into the cell nucleus resulting in inhibition of p53-mediated transcription, DNA repair, and apoptosis. These effects can be reversed if p53 concentrations and nuclear localization are increased through inhibition of proteasome-mediated p53 degradation. These types of interactions provide the rationale, from a mechanistic perspective, for targeting the ubiquitin-proteasome pathway in HCC.
Bortezomib, a small molecule, dipeptidyl boronic acid, is a selective and reversible inhibitor of the 26S proteasome. In pre-clinical studies, bortezomib has antitumor activity in a variety of in vitro and in vivo tumor models, either alone or in combination with common chemotherapeutic agents [13] [14] [15] [16] . Bortezomib has demonstrated activity in the clinic and is approved for the treatment of multiple myeloma patients, as well as for the treatment of refractory mantle cell lymphoma [17, 18] . The front-line multiple myeloma approval was largely based on an international, multicenter trial in which symptomatic multiple myeloma patients treated with a bortezomib-containing combination experienced a statistically significant improvement in the primary endpoint, time-to-progression. Bortezomib has been evaluated in other cancers and similarly demonstrated some clinical activity. A multicenter, single-arm, phase II trial was conducted to evaluate the activity of bortezomib in HCC.
Methods

Eligibility criteria
Patients eligible for the study had histologically or cytologically confirmed HCC that was surgically unresectable or metastatic. Measurable disease was required. Other eligibility criteria included Child-Pugh classification of A or B; an Eastern Cooperative Oncology Group performance status (PS) of 0, 1, or 2; an estimated life expectancy of at least 3 months; adequate bone marrow, hepatic, and renal function, indicated by an absolute neutrophil count ≥1,500/ μL, platelets ≥75,000/μL, and total bilirubin ≤3× upper limit of normal (UNL), respectively; serum AST or ALT levels ≤5× UNL; serum creatinine ≤2 mg/dL; serum albumin ≥2.5 g/dL; an international normalized ratio ≤1.5 (unless on anticoagulation). Patients had to provide written informed consent. Patients may not have received prior systemic chemotherapy and for individuals having prior liver-directed therapy (chemoembolization, cryotherapy, radiofrequency ablation, ethanol injection, or photodynamic therapy) the following criteria were required: >6 weeks had elapsed since therapy; indicator lesion(s) was/were outside the prior treatment area; or, if the only indicator lesion was inside the prior treatment area, there must have been clear evidence of disease progression associated with that lesion.
In addition, edges of the indicator lesion must have been clearly distinct on CT scanning. Exclusion criteria included the presence of >grade 1 sensory peripheral neuropathy of any etiology or grade 1 with neuropathic pain of any etiology, pregnancy, and a history of other malignancy within the previous 3 years (except for adequately treated basal cell or squamous cell skin cancer). Patients were also excluded on the basis of uncontrolled intercurrent illness, CNS metastases, and HIV infection. Institutional Review Board approval from each participating institution was required and the trial was monitored by the Mayo Clinic Data Safety Monitoring Board.
Bortezomib administration
Bortezomib was supplied by Millenium Pharmaceuticals through the National Cancer Institute (NCI; Bethesda, MD), and a dose of 1.3 mg/m 2 was administered intravenously as a bolus over 3-5 s. A cycle consisted of this dose administered on days 1, 4, 8, and 11 of a 21-day cycle. Treatment continued until disease progression, unacceptable toxicity, intercurrent illness that did not allow the patient to receive further treatment, or patient refusal. All toxicities were graded according to the Common Terminology Criteria for Adverse Events (CTCAE version 3.0) during treatment. Complete patient histories, physical examinations, complete blood cell counts (CBCs), and serum electrolytes/chemistries were performed at baseline and before each cycle of treatment. CBCs and electrolytes were monitored more frequently during the initial two cycles. Alpha fetoprotein was measured every two cycles.
Disease assessment
The primary endpoint of the trial was the confirmed tumor responses assessed using RECIST criteria [19] . All patients meeting the eligibility criteria who signed a consent form, began treatment, and had at least one postbaseline disease assessment were considered evaluable for assessing response. Radiologic studies were performed at baseline and after every two cycles (i.e., every 6 weeks) of therapy to assess tumor response. Total disappearance of target lesions constituted a complete response (CR); whereas a minimum of a 30% decrease in the sum of the LDs of the lesions was classified as a partial response (PR). New lesions or a 20% increase in the sum of the LDs of the target lesions or any increase in the size of number of non-target lesions, was considered progressive disease (PD). Otherwise, patients were classified as having stable disease (SD). Patients were re-evaluated for disease status after a minimum of 6 weeks of achieving a CR or PR to confirm the assessment. Similarly, an SD was re-assessed at a minimum interval of 6 weeks. Patients with global deterioration of health status requiring discontinuation of treatment without objective evidence of disease progression at that time, and not related to study treatment or other medical conditions, were considered to have PD due to symptomatic deterioration. For the primary endpoint of the study, a confirmed tumor response was defined to be either a CR or PR on 2 consecutive evaluations at least 6 weeks apart during the first 12 cycles of treatment.
Other endpoints included duration of response which was calculated from the first date of a patient's objective status of either a CR or PR to the date of PD (or last tumor assessment). Duration of SD was calculated from the date of registration to the date of PD (or last tumor assessment if no PD) for patients having achieved a best response of SD. Patients were censored for progression (survival) at their date of last assessment (last contact) if no progression (death) occurred. Time to PD was calculated from the date of registration to the date of PD (or last tumor assessment). Survival or time to death was calculated from the date of registration to the date of death (or last contact). All patients were followed for a maximum of death or 3 years following registration, whichever was earlier.
Statistical design A Simon two-stage phase II study design [20] was used to test whether there was sufficient evidence to determine that the proportion of confirmed tumor responses was at least 30% (i.e., warranted further study) versus 15% (i.e., clinically inactive). Four confirmed responses in the initial 20 evaluable patients warranted the expansion of enrollment to 50 patients. Ten confirmed responses among 50 evaluable patients was considered sufficient evidence of promising activity to recommend further testing of this regimen. This design yielded 88% power at 0.09 level of significance to detect a true response rate of 30%. Confidence intervals (CIs) were calculated using the method of Duffy-Santner [21] . Accrual was not suspended between stages allowing for continued patient entry while the planned early response analysis was performed. Toxicity was closely monitored with a low rate being observed. A toxicity stopping rule was in place, as required by the Mayo Clinic Cancer Center Data Safety Monitoring Board.
Summary statistics and frequency tables were used to summarize baseline patient characteristics and adverse event rates. Adverse events are reported as a maximum severity per patient and type, across all cycles of treatment. All attributions collected for adverse events were reported unless otherwise noted. The Kaplan-Meier method [22] was used to estimate the distributions of time to progression and time to death. All analyses were conducted using SAS version 9.0. Two-sided p-values were reported, and p<.05 is considered statistically significant.
Results
Patient characteristics
Between January, 2004 and November, 2005, a total of 35 patients were accrued onto the study. Twenty-three patients were accrued in North America and twelve patients in Asia. All patients were eligible and began treatment. Baseline patient characteristics are summarized in Table 1 . The majority of patients were from the United States (66%) and male (80%). The median age was 61 yrs (21-77). 29 (85%) had Child-Pugh's classification of A (vs. B). Some patients (46%) of the patients presented with baseline chronic liver disease such as chronic or viral hepatitis.
Treatment administration
Thirty-five patients completed a total of 88 cycles of treatment (median of 2 cycles, range 1 to 12). At least one bortezomib treatment was omitted for 24 of those cycles and 12 patients required at least one dose reduction on a total of 15 cycles. The reasons for dose reductions were hematologic nadirs (11 cycles) and non-hematologic adverse events (4 cycles-grade 3 diarrhea, skin rash, grade 2 hip pain, grade 1 abdominal pain). Reductions occurred as early as cycle 2 (9 pts) and as late as cycle 10 (1 pt). Reasons for discontinuation of protocol treatment included: progression (60%), refusal (17%), adverse reactions (17%), and miscellaneous reasons (6%, e.g. death during treatment, alternative treatment, or other medical problems).
Toxicity
All 35 patients were evaluable for toxicity. The most common all grade AEs considered possibly related to treatment were thrombocytopenia (71%), diarrhea (46%), anemia (43%), fatigue and leukopenia (both 40%) and nausea (31%). A frequently reported bortezomib related side effect, neuro-sensory changes, was seen at grade 1 (11%) and 2 (6%) intensities. Grade 3 or higher AEs considered at least possibly related to study treatment are summarized in Table 2 . Only thrombocytopenia was observed in greater than 10% of patients. Fifteen individuals experienced grade 3 AEs and four patients experienced grade 4 AEs considered at least possibly related to study treatment. Grade 4 events included: thrombosis (2), hepatic failure (1), and hypoglycemia (1).
Efficacy
Twenty-seven of the 35 patients were evaluable for the primary endpoint, confirmed tumor response. One confirmed partial response was observed in a 71 year old white male who achieved a PR at cycle 6 and continued on bortezomib until cycle 11 (sustained 3.1 months), before moving to an alternate treatment. He ultimately died from this cancer 8.5 months after discontinuing bortezomib while under hospice care at home. The CT scans (Fig. 1 ) from this patient suggest some degree of tumor necrosis (an effect similarly reported in the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) sorafenib trials) [4] . The confirmed response rate for this trial therefore was 4% (95% CI 0-19%). The pre-study interim analysis criteria dictated that at least 30% of patients (4 of the initial 20 evaluable patients) achieve confirmed tumor responses to warrant continuation of accrual. The trial was thereby permanently closed at the interim analysis although additional patients were accrued while the analysis was being completed. Nine patients experienced a best response of SD, lasting a median of 2.8 months (95% CI 2.8-9.0 months). Overall, the majority (77%) of patients experienced disease progression, and thirty-one patients have died. Of the surviving patients, median follow-up time was 11.4 months (range 1.7-20.2). The estimated time to progression was 1.6 months (95% CI 1.4-2.2 months). The estimated median survival time for all patients was 6.0 months (95% CI 3.9-7.8 months). Table 3 and Fig. 2 provide estimates of the distributions of time to progression and survival. Six patients died within 60 days of initiating cycle 1 of study treatment; all were considered unlikely related to therapy. A 61 year old Caucasian male presenting with a history of chronic viral hepatitis, Child-Pugh B, a primary hepatic site of disease and distant nodal metastases, refused further treatment after 18 days and having only grade 1 adverse events reported. This patient subsequently died 23 days later and of reasons secondary to their cancer. A 74 year old Caucasian male, Child-Pugh B, with a primary hepatic site of disease experienced clinical deterioration precluding further treatment by day 21, after experiencing grade 4 liver failure based on encephalopathy considered secondary to study treatment, combined with grade 3 fatigue and thrombocytopenia considered unrelated to study treatment. This patient died 19 days later and of cancer related causes. A 70 year old Caucasian male with a history of kidney stones, symptomatic gout, smoking, hypertension, hemochromatosis managed by phlebotomies, ChildPugh A function, received only two of the treatments during cycle 1 discontinued treatment due to left upper quadrant pain caused by hepatic and pulmonary metastases. Nearly a month later, this patient was hospitalized due to pain caused from an upper lobe pulmonary embolism. A week later, a CT scan ordered due to extreme shortness of breath and abdominal pain showed catastrophic intraabdominal bleeding, most likely coming from a hypervasularized hepatic tumor. The patient died in the emergency room, 25 days after being registered to this study and of a lower GI hemorrhage. A 43 year old Asian male, Child-Pugh A, with advanced localized hepatic disease experienced grade 3 adverse events considered unrelated to treatment (abdominal pain and vomiting) and after receiving 2 cycles of treatment. This patient died 52 days after going on study following the appearance of nodal and hepatic lesions as well as clinical deterioration. A 77 year old Asian male, Child-Pugh B, with localized advanced disease discontinued after receiving one course of treatment due to grade 5 bilirubin considered secondary to the deranged hepatic function. This patient died 55 days after registration and of reasons secondary to their cancer. Finally, a 74 year old Caucasian male with Child-Pugh B function and metastasis on the right adrenal gland discontinued study treatment during their second cycle due to increasing hepatic and metastatic lesions, as well as new lesions. This patient died 59 days after registration.
Discussion
HCC represents one of the most challenging cancers to treat especially in the advanced setting. In general, HCC cells are inherently resistant to most cytotoxic chemotherapy.
Patients are afflicted with a tumor burden that affects their performance status but also have compromised hepatic function that limits their tolerance of conventional chemotherapy. In addition, variations in the types of HCC exist and can be attributed to the different etiologies of the disease, for example, HCV versus HBV, and their distinct roles in hepatocarcinogenesis. These distinctions impact which specific molecular derangements are present in a given patient's cancer and how they will ultimately respond to a specific therapeutic agent. Targeted agents are potentially more useful in HCC treatment since they hypothetically have a more favorable therapeutic indexmore direct inhibition of tumor growth with less associated side effects. The multikinase inhibitor, sorafenib, has increased survival in HCC patients and represents an important new targeted treatment that inhibits signaling of the raf kinase and the VEGF pathway [4] [5] [6] . In the pivotal Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol trial [5] that led to sorafenib's approval, the overall response rate was 2% with only seven patients achieving a partial response and no individuals experiencing a complete response. The positive findings of the trial can be attributed to the ability of sorafenib to delay tumor growth and progression as opposed to producing substantial tumor responses. In the examination of this trial in this context, bortezomib treatment did not result in a significant response rate nor was tumor growth delayed as reflected by the short 1.6-month time to progression. This translated into a median survival equivalent to the control arm of the SHARP trial. It can thus be argued that early pilot investigational trials in HCC may be better served with the endpoint of time to progression or measure of disease stabilization as opposed to a primary endpoint of response as was done in this trial.
The reasons bortezomib exhibited little activity in HCC patients in this trial requires examination. Bortezomib may not significantly inhibit ubiquitin-proteasome pathway in HCC cells, or alternatively, this specific pathway may not be as critical to HCC proliferation and survival as proposed. Additionally, the bortezomib dose and schedule used in this study may be a reason for the lack of activity. Despite sound pre-clinical data that reversal of viral proteinmediated cell proliferation and other malignant processes can be achieved with proteasome inhibition, these alterations may not occur to a significant enough extent to be clinically meaningful. Interestingly, tumor necrosis was observed in the sole responding patient, similar to what was seen the early investigations with sorafenib [4] . Relationships between survival and either hepatitis status or site of enrollment were explored (data not shown). Intriguingly, individuals with underling viral hepatitis had a one-month longer TTP and non-Asia patients experienced a two month longer survival. No difference in outcome was observed based on specific hepatitis viral infection, B vs. C. In the study, patients received only two cycles on average, one confirmed response was observed, and 77% of individuals experienced disease progression. This either suggests that the enrolled patients had rapidly progressive disease or that bortezomib has essentially no activity in delaying tumor growth. Patients, on average, survived 5 months beyond progression suggesting that subsequent, second-line therapies influenced the observed median survival. It is intriguing to note that in the SHARP trial, up to 48% of patients had prior local or liver-directed therapy, such as radiofrequency ablation or chemoembolization. In our study, only 7 (20%) patients had received prior liver-directed treatment. In both trials, patients had to have exhibited disease progression to be eligible which can be challenging to determine in previously treated hepatic lesions. Progression of only one of several metastases constitutes progression and thus qualifies a patient for study entry. This is important for understanding treatment effects of targeted agents which in general are cytostatic as opposed to cytotoxic.
The observed toxicity was not excessive as the only grade 3 or higher toxicity reported in more than 10% of patients was thrombocytopenia. Six patients died within 60 days of receiving bortezomib, with two individuals dying during active treatment. Furthermore, worsening hepatic function appeared to be a common occurrence in these six individuals. Whether this can directly be attributed to bortezomib is unknown. Interestingly, laboratory studies suggest that proteasome inhibition may attenuate hepatic injury by reducing hepatocyte apoptosis and liver fibrosis [23, 24] . This however occurs with concomitant hepatocyte proliferation. In addition, bortezomib is primarily metabolized by cytochrome P-450 enzymes and decreased clearance may result in patients with hepatic dysfunction.
The issue remains that despite intriguing preclinical rationale for the use of proteasome inhibitors for the treatment of HCC, does bortezomib have a future in HCC? Bortezomib has minimal activity in other cancers including breast, renal cell, colorectal and pancreatic cancers [25] [26] [27] [28] [29] . In HCC, a phase I/II trial with bortezomib with the same schedule has been performed [30] . In this trial, 18 patients with measurable, unresectable disease were treated; both Child-Pugh A and B (13/5 patients) and hepatitis B and/or C (7 patients) were included. Doses of 1.0 and 1.3 mg/m2 were evaluated with the latter being declared the MTD. A mean of 4.5 cycles was administered and no responses were observed while seven patients experienced stable disease lasting greater than 8 weeks. Similar to approaches in other cancers and because preclinical data reveals additive interactions, bortezomib combined with adriamycin (15-20 mg/m2 every 21 days) was evaluated in HCC in a phase II by Berlin and colleagues [31] . Only one response (2.3%) was seen while 10 (25.6%) patients had stable disease. Similar to historical reports of adriamycin alone in HCC, the median OS was 5.7 months and PFS was 2.4 months leading the authors to conclude that the combination did not show sufficient activity to warrant further investigation.
In summary, this trial demonstrated that bortezomib, administered alone at a dose of 1.3 mg/m2 twice weekly for two of every 3 weeks, has minimal single-agent clinical activity in patients with advanced, unresectable HCC.
